Comparative study of the impact of diet versus pravastatin on color vision in brodman area 19 detected by computerized chromatic analysis (CARDIOCOLOUR Study);Estudio comparativo del impacto de la dieta frente a pravastatina en los centros de análisis cromático del área 19 de brodman, mediante el análisis computarizado cromático (Estudio CARDIOCOLOUR)

Revista Espanola de Cardiologia

Volumn 55, Issue 12, 2002, Pages 1243-1250

  Alcalá, Antonio ^a   Morell, Miguel ^a   Rius, Francisca ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Cholesterol; Coronary artery disease; Nervous system; Randomized study; Test

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ADULT; ARTICLE; BRAIN REGION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLOR VISION; COMPARATIVE STUDY; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036973152     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(02)76796-1     Document Type: Article

References (40)

1. Ball MJ, Murdoch GH. Neuropathological criteria for the diagnosis of Alzheimer's disease: are we really ready yet? Neurobiol Aging 1997; 18(Suppl 4):31-7.
2. Meyer JS, Terayama Y, Konno S, Akiyama H, Margishvili GM, Mortel KF. Risk factors for cerebral degenerative changes and dementia. Eur Neurol 1998;39:7-16.
3. Kawamata T, Akiguchi I, Yagi H, Irino M, Sugiyama H, Akiyama H. Neuropathological studies on strains of senescence accelerated mice with age-realted deficits in learning and memory. Exp Gerontol 1997;32:161-9.
4. Akiyama H, Meyer JS, Mortel KF, Terayama Y, Thornby JI, Konno S. Normal human aging: factors contributing to cerebral atrophy. J Neurol Sci 1997;152:39-49.
5. Celsis P. Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease? Ann Med 2000;32:6-14.
6. Poirier J. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Psychiatry Neurosci 1999; 24:147-53.
7. Alcalá A, Morell M, Rius F. El análisis computarizado cromático es un indicador precoz de riesgo cardiovascular asociado a hipercolesterolemia. Rev Esp Cardiol 2001;54:1417-25.
8. Shepherd J, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-7.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
10. Blauw GJ, Shepherd J, Murphy MB. Dementia and statins. PROSPER study group. Lancet 2001;357:881.
11. Vaughan CJ, Murphy MB, Buckley BM. Statins do more that just lower cholesterol. Lancet 1996;348:1079-82.
12. Allain CC, Poons L, Chang CS, Richmond W. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
13. Boccolo G, David H. Quantitative determination of serum tryglicerides by use of enzymes. Clin Chem 1973;19:476-82.
14. Assmann G, Shrlewer H, Schmitz G. Quantification of high density lipoprotein cholesterol by precipitation with fosfotungstic acid/MgCl2. Clin Chem 1983;29:2026-30.
15. Levatin P. Pupillary escape in disease of the retina or the optic nerve. Arch Ophthal 1959;62:768-79.
16. Thomson HS. Afferente pupillary defects: pupillary findings associated with defects of the afferent arm of the pupillary light reflex arc. Am J Ophthal 1966;62:860-83.
17. Schepens CL. Tecniques of examination of the fundus periphery. En: Mosby CV, editor. Transactions of the New Orleans Academy of Ophthalmology. New Orleans: St Louis, 1969; p. 39-51.
18. Kozlowski J. Telescopic eyepieces in indirect ophthalmoscopy. Retina 1984;4:60-2.
19. Sigelman J. Vitreous base classification of retinal tears: clinical aplication. Surv Ophthalmol 1980;25:59-74.
20. Fresco BB. A new tonometer-the pressure phosphene tonometer: clinical comparison with Goldman tonometry. Ophthal 1998; 105:2123-6.
21. Phelps CD, Hayreh ISS, Montaque PR. Comparison of visual fields defects in the low tension glaucomas with those in the high tension glaucomas. J Ophthalmol 1984;98:823-5.
22. Heijil A, Lindgren G, Olsson J. The effect of perimetric experience in normal subjects. Arch Ophthalmol 1989;107:81-6.
23. Traquair HM, Dort, NJ, Russel WK. Traumatic lesions of the chiasm. Brain 1935;58:398-9.
24. Gutowsky NJ, Heron JR, Scase MO. Early impairment of foveal magno and parvocellular pathways in juxtachiasmal tumours. Vision Res 1997;37:1401-8.
25. Alvarez SL, Pierce GE, Vingrys AJ, Benes SC, Weber PA, King-Smith PE. Comparison of red-green, blue-yellow and achromatic losses in glaucoma. Vision Res 1997;37:2295-301.
26. Porciatti V, Di Bartolo E, Nordi N, Fiorentini A. Responses to chromatic and luminance contrast in glaucoma: a psychophysical and electrophysiological study. Vision Res 1997;37:1975-87.
27. Tregear SJ, Knowhs PJ, Ripley LG, Casswell AG. Chromatic-Contrast threshold impairment in diabetes. Eye 1997;11:537-46.
28. Bazan NG, Packard MG, Teather L, Allan G. Bioactive lipids in excitatory neurotransmission and neural plasticity. Neurochem Int 1997;30:225-31.
29. Roth S. Role of nitric oxide in retinal cell death. Clin Neurosci 1997;5:216-23.
30. Hall ED, Andrus PK, Oostveen JA, Fleck TJ, Gurney ME. Relantionship of oxygen radical induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J Neurosci Res 1998;53:66-77.
31. -/- mice: isoform-specific effects on neurodegeneration. J Neurosci 1999;19:4867-80.
32. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 1998;18:2801-7.
33. Lund JS. Anatomical organization of macaque monkey striate visual cortex. Ann Rev Neurosci 1998;11:253-8.
34. Glaser JS. Neuro-ophthalmology. 2nd ed. Philadelphia: JB Lipincott Company, 1993; p. 69-70.
35. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer Disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-61.
36. Hart W. Adler Physiology of the eye. 9th ed. St Louis: Mosby-Year Book, Inc. 1992; p. 708-24.
37. Sample PA, Johnson CA, Haegerstrom-Portnoy G, Adams AJ. Optimum parameters for short-wavelenght automated perimetry. J Glaucoma 1996;5:375-83.
38. Wong N, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction. The Framingham Study. Ann Intern Med 1991;115:687-93.
39. Scandinavian Sinvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
40. Kellet J. Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors as predicted by decision analysis model. Eur J Surg 1997;163:539-46.